AbbVie Patent-Cliff Exposure & CMS Drug Spending Portfolio

AbbVie (North Chicago, IL): 127 reconciled FDA prescription therapies (18.6% 2025 to 2030 cliff risk), $32.24B 2024 CMS Part D & Medicaid spend, and 103 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterNorth Chicago, IL
Reconciled FDA Portfolio Therapies127
2025 to 2030 Patent-Cliff Revenue Exposure18.6%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$32.24B
2024 Medicare Part D Spend$21.58B
2024 Medicaid Spend$10.66B
California HCAI SB 17 Filings103 WAC filings (max 24.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.